FTC Accuses Three Drugmakers of Anti-Competitive Actions
The Federal Trade Commission said Monday it filed a complaint against Schering-Plough (SGP), Upsher-Smith and American Home Products (AHP), accusing the drug makers of entering into an illegal anticompetitive agreement to keep low-cost, generic drugs off the market.
In an administrative complaint, the FTC claimed Schering-Plough illegally paid Upsher-Smith and American Home Products millions to delay the launch of their generic versions of K-Dur, a widely prescribed potassium chloride supplement made by Schering-Plough. The commission alleges the agreements have cost consumers more than $100 million.
A federal administrative law judge will hear the FTC's complaint.Schering-Plough lost 53 cents, or 1.4%, to $36 in recent trading on the New York Stock Exchange. American Home Products fell $1.26, or 2.1%, to $57.49.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts